C4 Therapeutics, Inc.
CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkinā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.01
Price-0.56%
-$0.02
1Y
Price
Market Cap
$443.086m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-379.2%
EBITDA Margin-408.5%
Net Profit Margin-487.8%
Free Cash Flow Margin-379.2%
EBITDA Margin-408.5%
Net Profit Margin-487.8%
Free Cash Flow MarginRevenue
$34.861m
-3.0%
1y CAGR+23.2%
3y CAGR+9.1%
5y CAGREarnings
-$103.801m
+1.1%
1y CAGR+7.3%
3y CAGR+4.7%
5y CAGREPS
-$1.19
+6.3%
1y CAGR+21.9%
3y CAGR+16.0%
5y CAGRBook Value
$234.247m
$328.861m
Assets$94.614m
Liabilities$58.447m
DebtDebt to Assets
17.8%
-0.6x
Debt to EBITDAFree Cash Flow
-$96.024m
+3.3%
1y CAGR-3.0%
3y CAGR-1.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company